...By Danielle Golovin, Staff Writer KalVista gained $17.89 (114%) to $33.50 on Tuesday after reporting its...
...PGI-C) scale and achieved symptom relief more quickly (p<0.0001) using a composite Visual Analogue Scale (VAS).KalVista...
...Pharmaceuticals Inc. (NASDAQ:BCRX), marking the first approval for an orally administered non-steroidal option to prevent HAE. KalVista...

...Lewis previously led the global talent acquisition organization at Biogen Inc. (NASDAQ:BIIB). Protease inhibitor company KalVista...
...NASDAQ:KALV) said CFO Benjamin Palleiko will take on the additional role of CBO. He is KalVista’s...
...CEO Shenda Baker, who remains CSO and a director. BioCentury Staff Axcella Health Inc. Epic Sciences Inc. Imara Inc. Juvenescence Ltd. KalVista...

...Venrock invested in KalVista Pharmaceuticals Inc. (NASDAQ:KALV) and BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) before backing Attune. KalVista...
...in the lead” for prophylaxis, though it has had clinical issues around gastrointestinal adverse events. KalVista's...

...effects as a problem in the product profile or as a negative compared to competitors. KalVista...
...Berndt Modig Patents: None issued Companies and Institutions Mentioned BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX), Durham, N.C. KalVista...
...receptor Complement 1 (C1) esterase KLKB1 - Plasma kallikrein Mary Romeo, Staff Writer BCX7353 Firazyr, icatibant (JE049) KVD818 BioCryst Pharmaceuticals Inc. KalVista...

...Data are expected by YE18. The company did not respond to requests for an interview. KalVista...
...Express Scripts Holding Co. (NASDAQ:ESRX), St. Louis, Mo. Hereditary Angioedema Association (HAEA), Fairfax City, Va. KalVista...
...maker.” BioCentury (2015) Usdin, S. “HAE’s tightening timeline.” BioCentury (2008) Virginia Li, Staff Writer BCX7353 Haegarda KVD818 subcutaneous C1-INH BioCryst Pharmaceuticals Inc. KalVista...

...KLKB1) inhibitor, along with future oral plasma kallikrein inhibitors to treat diabetic macular edema (DME). KalVista...
...milestones for each program, as well as tiered royalties. Merck also invested $9.1 million in KalVista...
...KalVista Pharmaceuticals Inc. (NASDAQ:KALV), Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Ophthalmic Jennie Walters KVD001 KalVista...

...kallikrein inhibitor (KLKB1), along with future oral plasma kallikrein inhibitors to treat diabetic macular edema. KalVista...
...milestones for each program, as well as tiered royalties. Merck also invested $9.1 million in KalVista...
...a private placement, giving it a 9.9% stake. The price is a 16% premium to KalVista's...

...Carbylan will merge with KalVista in a stock deal, with KalVista expected to own an 81%...
...to own an 81% stake in the combined company. The combined company will focus on KalVista’s...
...kallikrein inhibitor , that has completed Phase I testing to treat diabetic macular edema (DME). KalVista...

...Longwood Fund and Venrock and existing investors Novo A/S and SV Life Sciences also participated. KalVista...
...angioedema (HAE). RA Capital's Rajeev Shah and Longwood Fund's Rich Aldrich will join KalVista's board. KalVista...